Avid Bioservices, Inc. (NASDAQ:CDMO) is trending higher in the market today as the company shares are trading 3.55% or 0.18 points up from last closing price of $5.07, reaching $5.25 at last check. Any clue why there is so much of action in the CDMO stock? The share price has risen in 2 of the last 5 days and is up 28.35% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -491,055 shares, and in total 303945 shares valued at $1.596 million were seen changing hands compared with 795000 shares valued at $4.031 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in CDMO stock for the next couple of days.
Avid Bioservices, Inc. (CDMO) shares have notched a 3-month gain of about 28.35%, but has still advanced 23.66% year to date. By comparison, the stock sank -28.79% over the past 12 months, while it slipped -21.76% over the 1 month. The company’s market cap is around $370.21M, with its short interest ratio standing at 3.56%.
In the current trading session for CDMO, the stock witnessed two major price actions, it rose to a high of $5.31 and was down as much as $4.89 at one point. The high recorded is very low when compared to their 52-week high which is $3.37. The 52-week high is now at -37.74 distance from current price. Their recent low of $8.44 represents a 55.93% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for CDMO is $9.17, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Avid Bioservices, Inc. earned $-0.17 per share in the trailing 12 months and has a P/E ratio of -30.88. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 30.46 and lower compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. CDMO also has P/S multiple of 7.15. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.34x.
The company recorded an interesting insider sale transaction by the Director on Sep 20, 2018. A Securities and Exchanges Commission filings show that Joel Mccomb sold a total of 50,000 CDMO shares that day for a sum of around $326,500. Avid Bioservices, Inc. (CDMO) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded no shares in the business, which makes up 0% of 54,578 shares that were traded over a year. In the past 12 months, insiders have purchased 4,578 shares while the seller parted with 50,000 shares.
CDMO‘s last price was up 10.07% as compared to the average trading price of 50 days recorded at $4.77 while enlarging the period to 200 trading days, the average closing price was $6.38. At present, there are 73.02 million in the total number of common shares owned by the public and among those 49.71 million shares have been available to trade. The percentage of shares being held by the company management was 11.62% while institutions stake was 53%. The company has generated negative returns on equity over the last 12 months (-20.6%). It managed to keep its gross profit margin at 13.5% over the past 12 months.
When assessing the full upside of the CDMO stock, there is another set of technicals that should be looked into and considered. Its -19.18% decline from moving average of $6.5 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 2.76 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Avid Bioservices, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $10.5 on shares of Avid Bioservices, Inc. (NASDAQ:CDMO), which corresponds to 99.24% upside potential than its current market price of $5.25 and implies potential despite the recent advance in the price. However, their current target price has fallen from $10.5 a month ago and is up handily from the consensus target of $8 a quarter ago.
In the last five years, the EPS of the company has been roughly 35.4%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 19.1 over the last five years. The company recently recorded an increase of 147.8%, but this figure is rather attractive.